natgillin/translations-raw huggingface dataset:
Pakninger med 5, 6, 10, 12, 15, 18, 20, 30, 50, 60, 90 og 100 smeltetabletter.
Packs of 5, 6, 10, 12, 15, 18, 20, 30, 50, 60, 90 and 100 orodispersible tablets.
Sådan skal du tage Aerius smeltetabletter
How to take Aerius orodispersible tablet
Hvis du holder op med at tage Aerius smeltetabletter Spørg lægen, apotekspersonalet eller sundhedspersonalet, hvis der er noget du er i tvivl om.
If you stop taking Aerius orodispersible tablet If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Tag udelukkende Aerius således, som det er ordineret til dig.
Take Aerius only as it is prescribed for you.
I kontrollerede kliniske studier, hos voksne og unge var der ingen overhyppighed af døsighed sammenlignet med placebo ved den anbefalede dosis på 5 mg daglig.
In controlled clinical trials, at the recommended dose of 5 mg daily for adults and adolescents, there was no excess incidence of somnolence as compared to placebo.
Aerius 2,5 mg smeltetabletter desloratadin
Aerius 2.5 mg orodispersible tablets desloratadine
• hurtig hjerterytme (puls)
● fast heartbeat
EU/1/00/160/037 5 smeltetabletter EU/1/00/160/038 6 smeltetabletter EU/1/00/160/039 10 smeltetabletter EU/1/00/160/040 12 smeltetabletter EU/1/00/160/041 15 smeltetabletter EU/1/00/160/042 18 smeltetabletter EU/1/00/160/043 20 smeltetabletter EU/1/00/160/044 30 smeltetabletter EU/1/00/160/045 50 smeltetabletter EU/1/00/160/046 60 smeltetabletter EU/1/00/160/047 90 smeltetabletter EU/1/00/160/048 100 smeltetabletter
EU/1/00/160/037 5 orodispersible tablets EU/1/00/160/038 6 orodispersible tablets EU/1/00/160/039 10 orodispersible tablets EU/1/00/160/040 12 orodispersible tablets EU/1/00/160/041 15 orodispersible tablets EU/1/00/160/042 18 orodispersible tablets EU/1/00/160/043 20 orodispersible tablets EU/1/00/160/044 30 orodispersible tablets EU/1/00/160/045 50 orodispersible tablets EU/1/00/160/046 60 orodispersible tablets EU/1/00/160/047 90 orodispersible tablets EU/1/00/160/048 100 orodispersible tablets
Det skal du vide, før du begynder at tage Aerius oral opløsning Sådan skal du tage Aerius oral opløsning Bivirkninger
What Aerius oral solution is and what it is used for What you need to know before you take Aerius oral solution How to take Aerius oral solution Possible side effects
Hvis du holder op med at tage Aerius oral opløsning Spørg lægen, apotekspersonalet eller sundhedspersonalet, hvis der er noget du er i tvivl om.
If you stop taking Aerius oral solution If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
I kontrollerede kliniske undersøgelser, var der ingen overhyppighed af døsighed sammenlignet med placebo ved den anbefalede dosis på 5 mg daglig.
In controlled clinical trials, at the recommended dose of 5 mg daily, there was no excess incidence of somnolence as compared to placebo.
Dette lægemiddel skal tages gennem munden.
This medicine is for oral use.
Aerius 5 mg filmovertrukne tabletter desloratadin
Aerius 5 mg film-coated tablets desloratadine
Aerius indeholder:
What Aerius contains
EU/1/00/160/049 5 smeltetabletter EU/1/00/160/050 6 smeltetabletter EU/1/00/160/051 10 smeltetabletter EU/1/00/160/052 12 smeltetabletter EU/1/00/160/053 15 smeltetabletter EU/1/00/160/054 18 smeltetabletter EU/1/00/160/055 20 smeltetabletter EU/1/00/160/056 30 smeltetabletter EU/1/00/160/057 50 smeltetabletter EU/1/00/160/058 60 smeltetabletter EU/1/00/160/059 90 smeltetabletter EU/1/00/160/060 100 smeltetabletter
EU/1/00/160/049 5 orodispersible tablets EU/1/00/160/050 6 orodispersible tablets EU/1/00/160/051 10 orodispersible tablets EU/1/00/160/052 12 orodispersible tablets EU/1/00/160/053 15 orodispersible tablets EU/1/00/160/054 18 orodispersible tablets EU/1/00/160/055 20 orodispersible tablets EU/1/00/160/056 30 orodispersible tablets EU/1/00/160/057 50 orodispersible tablets EU/1/00/160/058 60 orodispersible tablets EU/1/00/160/059 90 orodispersible tablets EU/1/00/160/060 100 orodispersible tablets
Aerius oral opløsning er pakket i flasker med 30, 50, 60, 100, 120, 150, 225 og 300 ml med børnesikkert låg.
Aerius oral solution is available in bottles of 30, 50, 60, 100, 120, 150, 225 and 300 ml, with a childproof cap. For all packages except the 150 ml bottle, a measuring spoon is provided, marked for doses of 2.5 ml and 5 ml.
Aerius oral opløsning lindrer symptomer forbundet med allergisk snue (irritation af vævet i de nasale passager forårsaget af allergi, for eksempel høfeber eller støvmideallergi) hos voksne, unge og børn i alderen 1 år og derover.
Aerius oral solution relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) in adults, adolescents and children 1 year of age and older.
Aerius lindrer symptomer forbundet med allergisk snue (irritation af vævet i de nasale passager forårsaget af allergi, for eksempel høfeber eller støvmideallergi) hos voksne og unge i alderen 12 år og derover.
Aerius relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) in adults and adolescents 12 years of age and older.
Aerius smeltetabletter indeholder:
What Aerius orodispersible tablet contains
Aerius 2,5 mg smeltetabletter
Aerius 2.5 mg orodispersible tablets
Aerius smeltetabletter lindrer symptomer forbundet med allergisk snue (irritation af vævet i de nasale passager forårsaget af allergi, for eksempel høfeber eller støvmideallergi) hos voksne, unge og børn i alderen 6 år og derover.
Aerius orodispersible tablet relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) in adults, adolescents and children 6 years of age and older.
Det skal du vide, før du begynder at tage Aerius smeltetabletter Sådan skal du tage Aerius smeltetabletter Bivirkninger
What Aerius orodispersible tablet is and what it is used for What you need to know before you take Aerius orodispersible tablet How to take Aerius orodispersible tablet Possible side effects
Aerius 5 mg smeltetabletter desloratadin
Aerius 5 mg orodispersible tablets desloratadine
citronsyre, vandfri dinatriumedetat vand renset
sodium citrate dihydrate, natural and artificial flavour (bubblegum), citric acid anhydrous, disodium edetate, purified water
Aerius smeltetabletter lindrer symptomer forbundet med allergisk snue (irritation af vævet i de nasale passager forårsaget af allergi, for eksempel høfeber eller støvmideallergi) hos voksne og unge i alderen 12 år og derover.
Aerius orodispersible tablet relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) in adults and adolescents 12 years of age and older.
Mundtørhed
Jaundice
• svimmelhed
● drowsiness
Hvis du holder op med at tage Aerius Spørg lægen, apotekspersonalet eller sundhedspersonalet, hvis der er noget du er i tvivl om.
If you stop taking Aerius If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Det skal du vide, før du begynder at tage Aerius Sådan skal du tage Aerius Bivirkninger
What Aerius is and what it is used for What you need to know before you take Aerius How to take Aerius
• kvalme
● seizures
Reaktionsbuffer: 1 ml
Reaction Buffer: 1 ml
Pulver til injektionsvæske, opløsning: 40 mikrogram;
Powder for solution for injection: 40 micrograms;
Radiofarmaceutisk præparationssæt
Kit for radiopharmaceutical preparation
Reaktionsbuffer: hætteglas (COP)
Reaction Buffer: vial (COP)
1 hætteglas + 1 hætteglas
1 vial + 1 vial
DATO FOR FØRSTE TILLADELSE/FORNYELSE AF TILLADELSEN Dato for første markedsføringstilladelse: 08/09/2015
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 08/09/2015
Nedenstående tabel kan bruges som vejledning.
The table below may be used for guidance.
Den gennemsnitlige plasmaproteinbinding in vitro er 93 %.
The mean plasma protein binding in vitro is 93%.
Dosis og behandlingsplan:
Dose and treatment schedule:
ATCvet-kode: QC09BX90
ATCvet code: QC09BX90
Hundens vægt (kg)
Body weight (kg) of dog
- Meget sjælden (færre end 1 dyr ud af 10.000 dyr, herunder isolerede rapporter).
- very rare (less than 1 animal in 10,000 animals, including isolated reports).
I tilfælde af overdosering skal hunden behandles symptomatisk.
In case of overdose the dog should be treated symptomatically.
FORTEKOR PLUS-tabletter bør administreres oralt, to gange dagligt, med 12 timers mellemrum (morgen og aften) og ca. 1 time før fodring.
FORTEKOR PLUS tablets should be administered orally, twice daily 12 hours apart (morning and evening) and approximately 1 hour before feeding.
Et lille antal hunde kan udvise forbigående opkastning, manglende koordination eller tegn på træthed.
A small number of dogs may exhibit transient vomiting, incoordination or signs of fatigue.
Opbevaringstid for veterinærlægemidlet i salgspakning: 18 måneder
Shelf life of the veterinary medicinal product as packaged for sale: 18 months
SÆRLIGE OPBEVARINGSBETINGELSER Opbevares ved temperaturer under 25 °C.
SPECIAL STORAGE CONDITIONS Store below 25 °C.
Efter oral administration af pimobendan alene er den absolutte biotilgængelighed af det aktive stof 60-63 %.
Following oral administration of pimobendan alone the absolute bioavailability of the active ingredient is 60-63%.
Brug ikke dette veterinærlægemiddel efter den udløbsdato, der står på blisterpakningen og kartonen efter EXP.
Do not use this veterinary medicinal product after the expiry date which is stated on the blister and carton after EXP.
Behandling bør bestå af intravenøs(e) infusion(er) af varmt isotonisk saltvand efter behov.
Therapy should consist of intravenous infusion(s) of warm isotonic saline as required.
Yderligere metaboliske veje er fase II-glucuronider og sulfater.
Further metabolic pathways are phase II, glucuronides and sulfates.
ANGIVELSE AF DE(T) AKTIVE STOF(FER) OG ANDRE INDHOLDSSTOFFER Hver tablet indeholder
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) Each tablet contains
4.10 Overdosering (symptomer, nødforanstaltninger, modgift), om nødvendigt I tilfælde af overdosering skal hunden behandles symptomatisk.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary In case of overdose the dog should be treated symptomatically.
FREMSTILLER ANSVARLIG FOR BATCHFRIGIVELSE B. BETINGELSER ELLER BEGRÆNSNINGER VEDRØRENDE UDLEVERING OG BRUG C. ANGIVELSE AF MRL-VÆRDIER
MANUFACTURER RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. STATEMENT OF THE MRLs
FORTEKOR PLUS er et fast kombinationsprodukt, som kun bør anvendes til hunde, der har brug for samtidig administration af begge aktive stoffer i denne faste dosis.
FORTEKOR PLUS is a fixed combination product which should only be used in dogs which require both active substances to be administered concomitantly at this fixed dose.
Interaktion med andre lægemidler og andre former for interaktion: Fortæl dyrlægen, hvis du bruger anden medicin til din hund eller har gjort det for nylig.
Interactions with other medicinal products and other forms of interaction: Inform the veterinary surgeon if the animal is taking, or has recently taken, any other medicines.
Efter oral administration af benazeprilhydrochlorid alene er den systemiske biotilgængelighed ufuldstændig (~13 %) hos hunde på grund af ufuldstændig absorption (38 %) og first-pass metabolisme.
After oral administration of benazepril hydrochloride alone, the systemic bioavailability is incomplete (~13%) in dogs due to incomplete absorption (38%) and first pass metabolism.
Begge tabletstyrker er pakket i aluminium/aluminium-blisterpakninger i en ydre karton.
Both tablet strengths are packaged in aluminium/aluminium blisters packaged into an outer cardboard box.
Opbevar blisterpakningen i den ydre karton for at beskytte mod fugt.
Keep the blister in the outer carton in order to protect from moisture.
Virkningen og sikkerheden af produktet er ikke blevet fastlagt hos hunde under 2,5 kg eller under 4 måneder.
The efficacy and safety of the product has not been established in dogs below 2.5 kg bodyweight or under 4 months of age.
Gentagen administration af benazeprilhydrochlorid fører til let bioakkumulation af benazeprilat (R = 1,47), og steady-state opnås inden for få dage (4 dage).
Repeated administration of benazepril hydrochloride leads to slight bioaccumulation of benazeprilat (R = 1.47), steady state being achieved within a few days (4 days).
DATO FOR SENESTE GODKENDELSE AF INDLÆGSSEDLEN Yderligere information om dette lægemiddel er tilgængelig på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu/.
DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED Detailed information on this product is available on the website of the European Medicines Agency http://www.ema.europa.eu/.
Nyrefunktion og tegn på hypotension (letargi, svaghed osv.) bør monitoreres nøje og behandles om nødvendigt.
Renal function and signs of hypotension (lethargy, weakness, etc) should be monitored closely and treated as necessary.
Da biotilgængeligheden reduceres væsentligt, når pimobendan gives samtidig med eller kort tid efter fødeindtagelse, anbefales det, at tabletterne gives ca. 1 time før fodring.
Since this bioavailability is considerably reduced when pimobendan is administered with food or shortly thereafter, it is recommended to treat animals approximately 1 hour before feeding.
Må ikke anvendes til drægtige eller diegivende hunde (se afsnittet “SÆRLIG(E) ADVARSEL/ADVARSLER").
Do not use in pregnant or lactating dogs (see section “SPECIAL WARNINGS").
Kontakt din dyrlæge eller apotekspersonalet vedrørende bortskaffelse af lægemidler, der ikke længere findes anvendelse for.
Ask your veterinary surgeon or your pharmacist how to dispose of medicines no longer required.
Farmakoterapeutisk gruppe: ACE-hæmmere, kombinationer.
Pharmacotherapeutic group: ACE inhibitors, combinations.
Personer med kendt overfølsomhed over for pimobendan eller benazeprilhydrochlorid bør undgå kontakt med veterinærlægemidlet.
People with known hypersensitivity to pimobendan or benazepril hydrochloride should avoid contact with the veterinary medicinal product.
Gravide kvinder bør være særligt omhyggelige med at undgå utilsigtet indtagelse, da ACE-hæmmere har vist sig at kunne påvirke det ufødte barn under graviditet hos mennesker.
Pregnant women should take special care to avoid accidental oral exposure because angiotensin converting enzyme (ACE) inhibitors have been found to affect the unborn child during pregnancy in humans.
Benazeprilat er en stærkt potent og selektiv hæmmer af ACE og forhindrer således omdannelsen af inaktivt angiotensin I til aktivt angiotensin II og reducerer derved også dannelsen af aldosteron.
Benazeprilat is a highly potent and selective inhibitor of ACE, thus preventing the conversion of inactive angiotensin I to active angiotensin II and thereby also reducing the synthesis of aldosterone.
FORTEKOR PLUS er en fast dosiskombination og bør kun bruges til patienter, hvis kliniske tegn er velkontrollerede ved administration af de samme doser af de enkelte komponenter (pimobendan og benazeprilhydrochlorid) indgivet samtidig.
FORTEKOR PLUS is a fixed dose combination and should only be used in patients whose clinical signs are successfully controlled by administration of the same doses of the individual components (pimobendan and benazepril hydrochloride) given concurrently.
Der er ingen signifikant forskel i farmakokinetikken af benazeprilat, når benazeprilhydrochlorid administreres til fodrede eller til fastende hunde.
There is no significant difference in the pharmacokinetics of benazeprilat when benazepril hydrochloride is administered to fed or fasted dogs.
I farmakologiske studier sås ingen interaktion mellem hjerteglykosidet ouabain og pimobendan.
In pharmacological studies no interaction between the cardiac glycoside ouabain and pimobendan was detected.
Det øger myofilamenternes følsomhed over for calcium og hæmmer phosphodiesterase (type III).
It increases the calcium sensitivity of cardiac myofilaments and inhibits phosphodiesterase (type III).
Disse bivirkninger er dosisafhængige og kan undgås ved at reducere dosis.
However, these effects are dose-dependent and can be avoided by reducing the dose in those cases.
Fordelingsvolumenet ved steady-state er 2,6 1/kg efter intravenøs administration af pimobendan alene, hvilket indikerer, at pimobendan let fordeles ud i vævet.
The volume of distribution at steady state is 2.6 l/kg after intravenous administration of pimobendan alone, indicating that pimobendan is distributed readily into the tissues.
Benazeprilat-koncentrationer aftager bifasisk: Den initiale hurtige fase (t1/2 = 1,7 timer) repræsenterer eliminering af frit stof, mens den terminale fase (t1/2 = 19 timer) afspejler frigivelsen af benazeprilat bundet til ACE, hovedsageligt i vævet.
Benazeprilat concentrations decline biphasically: the initial fast phase (t1/2 = 1.7 h) represents elimination of the free drug, while the terminal phase (t1/2 = 19 h) reflects the release of benazeprilat that was bound to ACE, mainly in the tissues.
Benazepril blokerer derfor effekterne medieret af angiotensin II og aldosteron, inklusiv vasokonstriktion af både arterier og vener, renal retention af natrium og vand og remodellerende effekter (inklusiv patologisk hjertehypertrofi og degenerative renale ændringer).
Therefore, benazepril blocks effects mediated by angiotensin II and aldosterone, including the vasoconstriction of arteries and veins, the retention of sodium and water by the kidney, and remodelling effects (including pathological cardiac hypertrophy and degenerative renal changes).
EU/2/15/185/004 (1 x 60 tabletter, 5 mg/10 mg)
EU/2/15/185/004 (1 x 60 tablets, 5 mg/10 mg)
Benazepril og benazeprilat er i udstrakt grad bundet til plasmaproteiner (85-90 %) og findes hovedsageligt i lunge-, lever- og nyrevæv.
Benazepril and benazeprilat are extensively bound to plasma proteins (8590%), and in the tissues they are found mainly in the lung, liver and kidney.
Clearance af benazeprilat påvirkes ikke hos hunde med nedsat nyrefunktion, og derfor er det ikke nødvendigt at justere dosis af FORTEKOR PLUS hos hunde med renal insufficiens.
The clearance of benazeprilat is not affected in dogs with impaired renal function; therefore no adjustment of the FORTEKOR PLUS dose is required in dogs with renal insufficiency.
Benazeprilat udskilles biliært (54 %) og renalt (46 %) hos hunde.
Benazeprilat is excreted via the biliary (54%) and urinary (46%) routes in dogs.
Interaktioner med kaliumbesparende diuretika såsom spironolakton, triamteren eller amilorid kan ikke udelukkes.
Interactions with potassium-sparing diuretics such as spironolactone, triamterene or amiloride cannot be ruled out.
Jernoxid, brun E172
Iron oxide brown E172
Maksimalniveauer for benazeprilat ses efter 1,9 timer med maksimale koncentrationer (Cmax) på 43,4 ng/ml.
Peak benazeprilat levels are seen after 1.9 h with peak concentrations (Cmax) of 43.4 ng/ml.
Det anbefales derfor at monitorere kaliumniveauer i plasma, når der anvendes FORTEKOR PLUS i kombination med et kaliumbesparende diuretikum på grund af risikoen for hyperkalæmi.
It is therefore recommended to monitor plasma potassium levels when using FORTEKOR PLUS in combination with a potassium sparing diuretic because of the risk of hyperkalaemia.
Hvide og lysebrune, ovale tolagstabletter med delekærv på begge sider.
White and light brown oval bilayer tablets with a score line on both sides.
OPLYSNINGER OM KORREKT ANVENDELSE FORTEKOR PLUS-tabletter kan om nødvendigt deles i to lige store dele.
ADVICE ON CORRECT ADMINISTRATION FORTEKOR PLUS tablets can be divided into halves if needed.
Det har også en vasodilaterende effekt ved at hæmme phosphodiesterase type III-aktiviteten.
It also exhibits a vasodilatory action through the inhibition of phosphodiesterase type III activity.
Hos hunde med kongestivt hjertesvigt er benazeprilhydrochlorid og pimobendan blevet givet sammen med digoxin og diuretika uden påviselige bivirkninger.
In dogs with congestive heart failure, benazepril hydrochloride and pimobendan have been given in combination with digoxin and diuretics without demonstrable adverse interactions.
Forbigående reversibel hypotension kan forekomme i tilfælde af utilsigtet overdosering.
Transient reversible hypotension may occur in accidental overdose.
En moderat øgning af plasmakreatininkoncentrationerne efter administration af ACEhæmmere er forenelig med reduktionen i glomerulær hypertension forårsaget af disse midler og er derfor ikke nødvendigvis en grund til at stoppe behandlingen, hvis der ikke er andre tegn.
A moderate increase in plasma creatinine concentrations following administration of ACE inhibitors is compatible with the reduction in glomerular hypertension induced by these agents, and is therefore not necessarily a reason to stop therapy in the absence of other signs.
Sikkerheden af FORTEKOR PLUS ikke blevet fastlagt i avlsdyr, drægtige eller diegivende hunde.
The safety of FORTEKOR PLUS has not been established in breeding, pregnant or lactating dogs.
I sjældne tilfælde er der observeret forbigående diarré, anoreksi eller letargi.
In rare cases transient diarrhoea, anorexia or lethargy have been observed.
Forbigående reversibel hypotension (lavt blodtryk) kan forekomme i tilfælde af utilsigtet overdosering.
Transient reversible hypotension (low blood pressure) may occur in accidental overdose.
Lactosemonohydrat Magnesiumstearat Majsstivelse
Lactose monohydrate Magnesium stearate
Bør ikke anvendes i tilfælde af hypertrofisk kardiomyopati eller kliniske tilstande, hvor en forøgelse af hjertets minutvolumen umuliggøres af funktionelle eller anatomiske årsager (f.eks. aorta- eller pulmonalstenose).
Do not use in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is not possible for functional or anatomical reasons (e.g. aortic or pulmonary stenosis).
Din dyrelæge vil måske anbefale en nøje overvågning af nyrefunktionen og tegn på lavt blodtryk (letargi, svaghed osv.) og om nødvendigt behandle disse symptomer.
Your veterinary surgeon may recommend to closely monitor kidney function and for signs of hypotension (lethargy, weakness etc) and treat these if necessary.
Efter oral administration af FORTEKOR PLUS-tabletter med to gange den anbefalede dosis til hunde nås maksimalniveauerne for begge stoffer hurtigt (Tmax 0,5 timer for benazeprilhydrochlorid og 0,85 timer for pimobendan) med maksimale koncentrationer (Cmax) for benazeprilhydrochlorid på 35,1 ng/ml og 16,5 ng/ml for pimobendan.
After the oral administration of FORTEKOR PLUS tablets at twice the recommended dose to dogs, peak levels of both compounds are attained rapidly (Tmax 0.5 h for benazepril hydrochloride and 0.85 h for pimobendan) with peak concentrations (Cmax) for benazepril hydrochloride of 35.1 ng/ml and 16.5 ng/ml for pimobendan.
Hos hunde med kronisk nyrelidelse kan benazepril øge plasmakreatininkoncentrationerne i starten af behandlingen.
In dogs with chronic kidney disease, benazepril may increase plasma creatinine concentrations at the start of therapy.
Croscarmellosenatrium Crospovidon
Croscarmellose sodium Crospovidone
Da pimobendan metaboliseres i leveren, bør produktet ikke administreres til hunde med svær leverinsufficiens.
As pimobendan is metabolised in the liver, the product should not be administered to dogs with severe hepatic insufficiency.
Laboratorieundersøgelser af rotter og kaniner med pimobendan har ikke vist nogen effekt på fertiliteten.
Laboratory studies in rats and rabbits with pimobendan have not shown any effect on fertility.